Search

Your search keyword '"Neelapu, Sattva"' showing total 2,135 results
Start Over Author "Neelapu, Sattva"
2,135 results on '"Neelapu, Sattva"'

351. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Author

Kim, Sang T., Chu, Yanshuo, Misoi, Mercy, Suarez-Almazor, Maria E., Tayar, Jean H., Lu, Huifang, Buni, Maryam, Kramer, Jordan, Rodriguez, Emma, Hussain, Zulekha, Neelapu, Sattva S., Wang, Jennifer, Shah, Amishi Y., Tannir, Nizar M., Campbell, Matthew T., Gibbons, Don L., Cascone, Tina, Lu, Charles, Blumenschein, George R., and Altan, Mehmet

Subjects
IMMUNE checkpoint inhibitors, CANCER treatment, ARTHRITIS
Abstract

This correction notice is for an article titled "Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy" published in Nature Communications. The correction states that the funding information for Jordan Kramer was omitted and should have been included in the original article. The corrected funding information is that J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028). The authors of the article are listed as Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, and Roza Nurieva. [Extracted from the article]

Published
2024
Full Text
View/download PDF

352. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

Author

Scholler, Nathalie, Perbost, Regis, Locke, Frederick L., Jain, Michael D., Turcan, Sarah, Danan, Corinne, Chang, Edmund C., Neelapu, Sattva S., Miklos, David B., Jacobson, Caron A., Lekakis, Lazaros J., Lin, Yi, Ghobadi, Armin, Kim, Jenny J., Chou, Justin, Plaks, Vicki, Wang, Zixing, Xue, Allen, Mattie, Mike, Rossi, John M., Bot, Adrian, and Galon, Jérôme

Abstract

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL.

Published
2022
Full Text
View/download PDF

353. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Author

Ghione, Paola, Palomba, M. Lia, Patel, Anik R., Bobillo, Sabela, Deighton, Kevin, Jacobson, Caron A., Nahas, Myrna, Hatswell, Anthony J., Jung, A. Scott, Kanters, Steve, Snider, Julia Thornton, Neelapu, Sattva S., Ribeiro, Maria Teresa, Brookhart, M. Alan, Ghesquieres, Herve, Radford, John, and Gribben, John G.

Abstract

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international SCHOLAR-5 cohort, which applied key ZUMA-5 trial eligibility criteria simulating randomized controlled trial conditions. SCHOLAR-5 data were extracted from institutions in 5 countries, and from 1 historical clinical trial, for r/r FL patients who initiated a third or higher line of therapy after July 2014. Patient characteristics were balanced through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. Time-to-event outcomes were evaluated using weighted Kaplan-Meier analysis. Overall response rate (ORR) and complete response (CR) rate were compared using weighted odds ratios. The 143 ScHOLAR-5 patients reduced to an effective sample of 85 patients after SMR weighting vs 86 patients in ZUMA-5. Median follow-up time was 25.4 and 23.3 months for SCHOLAR-5 and ZUMA-5. Median overall survival (OS) and progression-free survival (PFS) in SCHOLAR-5 were 59.8 months and 12.7 months and not reached in ZUMA-5. Hazard ratios for OS and PFS were 0.42 (95% confidence interval [CI], 0.21-0.83) and 0.30 (95% CI, 0.18-0.49). The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 and 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95% CI, 5.6-46.9) and 8.9 (95% CI, 4.3-18.3). Compared with available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints, suggesting axi-cel addresses an important unmet need for r/r FL patients. This trial was registered at www.clinicaltrials.gov as #NCT03105336.

Published
2022
Full Text
View/download PDF

354. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Cherng, Hua-Jay J., Sun, Ryan, Sugg, Bryant, Irwin, Russell, Yang, Haopeng, Le, Cao Cuong, Deng, Qing, Fayad, Luis, Fowler, Nathan H., Parmar, Simrit, Steiner, Raphael, Hagemeister, Fredrick, Nair, Ranjit, Lee, Hun Ju, Rodriguez, Maria, Samaniego, Felipe, Iyer, Swaminathan P., Flowers, Christopher R., Wang, Linghua, Nastoupil, Loretta J., Neelapu, Sattva S., Ahmed, Sairah, Strati, Paolo, Green, Michael R., and Westin, Jason

Abstract

Patients with relapsed or refractory large B-cell lymphomas (rrLBCL) can achieve long-term remission after CD19 chimeric antigen receptor T-cell therapy (CART19). However, more than half of recipients will experience treatment failure. Thus, approaches are needed to identify high-risk patients who may benefit from alternative or consolidative therapy. We evaluated low-pass whole-genome sequencing (lpWGS) of cell-free DNA (cfDNA) before CART19 as a new approach for risk stratification. We performed lpWGS on pretreatment plasma samples from 122 patients at time of leukapheresis who received standard-of-care CART19 for rrLBCL to define DNA copy number alterations (CNAs). In multivariable selection, high focal CNA score (FCS) denoting genomic instability was the most significant pretreatment variable associated with inferior 3-month complete response rates (28% vs 56%, P = .0029), progression-free survival (PFS; P = .0007; hazard ratio, 2.11), and overall survival (OS; P = .0026; hazard ratio, 2.10). We identified 34 unique focal CNAs in 108 (89%) patients; of these, deletion 10q23.3 leading to loss of FAS death receptor was the most highly associated with poor outcomes, leading to inferior PFS (P < .0001; hazard ratio, 3.49) and OS (P = .0027; hazard ratio, 2.68). By combining FCS with traditional markers of increased tumor bulk (elevated lactate dehydrogenase and >1 extranodal site), we built a simple risk model that could reliably risk stratify patients. Thus, lpWGS of cfDNA is a minimally invasive assay that could rapidly identify high-risk patients and may guide patient selection for and targeted therapies to evaluate in future clinical trials.

Published
2022
Full Text
View/download PDF

358. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Author

Kim, Sang T., Chu, Yanshuo, Misoi, Mercy, Suarez-Almazor, Maria E., Tayar, Jean H., Lu, Huifang, Buni, Maryam, Kramer, Jordan, Rodriguez, Emma, Hussain, Zulekha, Neelapu, Sattva S., Wang, Jennifer, Shah, Amishi Y., Tannir, Nizar M., Campbell, Matthew T., Gibbons, Don L., Cascone, Tina, Lu, Charles, Blumenschein, George R., and Altan, Mehmet

Abstract

Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of the mechanisms of arthritis-irAE is critical to overcome this challenge, but the pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and/or synovial fluid samples from 20 patients with arthritis-irAE, and unmask a prominent Th1-CD8+ T cell axis in both blood and inflamed joints. CX3CR1hi CD8+ T cells in blood and CXCR3hi CD8+ T cells in synovial fluid, the most clonally expanded T cells, significantly share TCR repertoires. The migration of blood CX3CR1hi CD8+ T cells into joints is possibly mediated by CXCL9/10/11/16 expressed by myeloid cells. Furthermore, arthritis after combined CTLA-4 and PD-1 inhibitor therapy preferentially has enhanced Th17 and transient Th1/Th17 cell signatures. Our data provide insights into the mechanisms, predictive biomarkers, and therapeutic targets for arthritis-irAE.Arthritis is the most common rheumatic immune-related adverse event (irAE) occurring in cancer patients receiving immune checkpoint inhibitors. Here the authors study the immune landscape of blood and synovial fluid samples from patients with arthritis-irAE, reporting immunological differences and similarities with classic autoimmune arthritis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

362. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Author

Locke, Frederick L., primary, Rossi, John M., additional, Neelapu, Sattva S., additional, Jacobson, Caron A., additional, Miklos, David B., additional, Ghobadi, Armin, additional, Oluwole, Olalekan O., additional, Reagan, Patrick M., additional, Lekakis, Lazaros J., additional, Lin, Yi, additional, Sherman, Marika, additional, Better, Marc, additional, Go, William Y., additional, Wiezorek, Jeffrey S., additional, Xue, Allen, additional, and Bot, Adrian, additional

Published
2020
Full Text
View/download PDF

363. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Author

Deng, Qing, primary, Han, Guangchun, additional, Puebla-Osorio, Nahum, additional, Ma, Man Chun John, additional, Strati, Paolo, additional, Chasen, Beth, additional, Dai, Enyu, additional, Dang, Minghao, additional, Jain, Neeraj, additional, Yang, Haopeng, additional, Wang, Yuanxin, additional, Zhang, Shaojun, additional, Wang, Ruiping, additional, Chen, Runzhe, additional, Showell, Jordan, additional, Ghosh, Sreejoyee, additional, Patchva, Sridevi, additional, Zhang, Qi, additional, Sun, Ryan, additional, Hagemeister, Frederick, additional, Fayad, Luis, additional, Samaniego, Felipe, additional, Lee, Hans C., additional, Nastoupil, Loretta J., additional, Fowler, Nathan, additional, Eric Davis, R., additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2020
Full Text
View/download PDF

364. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

Author

Pinnix, Chelsea C., primary, Gunther, Jillian R., additional, Fang, Penny, additional, Bankston, Mikaela E, additional, Milgrom, Sarah A., additional, Boyce, David, additional, Lee, Hun Ju, additional, Nair, Ranjit, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Westin, Jason, additional, Parmar, Simrit, additional, Rodriguez, M. Alma, additional, Nastoupil, Loretta, additional, Neelapu, Sattva, additional, Flowers, Christopher, additional, and Dabaja, Bouthaina S., additional

Published
2020
Full Text
View/download PDF

365. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Author

Nastoupil, Loretta J., primary, Jain, Michael D., additional, Feng, Lei, additional, Spiegel, Jay Y., additional, Ghobadi, Armin, additional, Lin, Yi, additional, Dahiya, Saurabh, additional, Lunning, Matthew, additional, Lekakis, Lazaros, additional, Reagan, Patrick, additional, Oluwole, Olalekan, additional, McGuirk, Joseph, additional, Deol, Abhinav, additional, Sehgal, Alison R., additional, Goy, Andre, additional, Hill, Brian T., additional, Vu, Khoan, additional, Andreadis, Charalambos, additional, Munoz, Javier, additional, Westin, Jason, additional, Chavez, Julio C., additional, Cashen, Amanda, additional, Bennani, N. Nora, additional, Rapoport, Aaron P., additional, Vose, Julie M., additional, Miklos, David B., additional, Neelapu, Sattva S., additional, and Locke, Frederick L., additional

Published
2020
Full Text
View/download PDF

366. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Author

Samaniego, Felipe, primary, McLaughlin, Peter, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, Fanale, Michelle, additional, Nastoupil, Loretta, additional, Rodriguez, Maria Alma, additional, Pro, Barbara, additional, Taylor, Erin, additional, Hagemeister, Fredrick B., additional, and Fowler, Nathan, additional

Published
2020
Full Text
View/download PDF

367. ABCL-122: Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1

Author

Locke, Frederick L., primary, Bartlett, Nancy L., additional, Jacobson, Caron A., additional, Oluwole, Olalekan O., additional, Munoz, Javier, additional, Lekakis, Lazaros J., additional, Topp, Max S., additional, Avivi, Irit, additional, Kim, Jenny J., additional, Chu, Rong, additional, Zheng, Lianqing, additional, Rossi, John M., additional, Bot, Adrian, additional, and Neelapu, Sattva S., additional

Published
2020
Full Text
View/download PDF

368. IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Author

Jacobson, Caron A., primary, Chavez, Julio C., additional, Sehgal, Alison R., additional, William, Basem M., additional, Munoz, Javier, additional, Salles, Gilles, additional, Casulo, Carla, additional, Munshi, Pashna N., additional, Maloney, David G., additional, Vos, Sven de, additional, Reshef, Ran, additional, Leslie, Lori A., additional, Yakoub-Agha, Ibrahim, additional, Oluwole, Olalekan O., additional, Fung, Henry C., additional, Plaks, Vicki, additional, Yang, Yin, additional, Lee, Jennifer, additional, Avanzi, Mauro P., additional, and Neelapu, Sattva S., additional

Published
2020
Full Text
View/download PDF

369. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, primary, Nastoupil, Loretta J., additional, Westin, Jason, additional, Fayad, Luis E., additional, Ahmed, Sairah, additional, Fowler, Nathan H., additional, Hagemeister, Fredrick B., additional, Lee, Hun J., additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Parmar, Simrit, additional, Rodriguez, Maria A., additional, Samaniego, Felipe, additional, Steiner, Raphael E., additional, Wang, Michael, additional, Pinnix, Chelsea C., additional, Adkins, Sherry, additional, Claussen, Catherine M., additional, Martinez, Charles S., additional, Hawkins, Misha C., additional, Johnson, Nicole A., additional, Singh, Prachee, additional, Mistry, Haleigh E., additional, Horowitz, Sandra, additional, George, Shirley, additional, Feng, Lei, additional, Kebriaei, Partow, additional, Shpall, Elizabeth J., additional, Neelapu, Sattva S., additional, Tummala, Sudhakar, additional, and Chi, T. Linda, additional

Published
2020
Full Text
View/download PDF

370. Abstract 2049: Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma

Author

Strati, Paolo, primary, Puebla-Osorio, Nahum, additional, Han, Guangchun, additional, Westin, Jason, additional, Nastoupil, Loretta, additional, Samaniego, Felipe, additional, Fowler, Nathan, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Flowers, Christopher, additional, Srour, Samer, additional, Watson, Grace, additional, Wang, Linghua, additional, Green, Michael, additional, and Neelapu, Sattva, additional

Published
2020
Full Text
View/download PDF

372. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission

Author

Glober, Gordon, primary, Gunther, Jillian, additional, Fang, Penny, additional, Milgrom, Sarah, additional, Korivi, Brinda Rao, additional, Jensen, Corey T., additional, Wagner-Bartak, Nicolaus A., additional, Ahmed, Sairah, additional, Lee, Hun Ju, additional, Nair, Ranjit, additional, Steiner, Raphael, additional, Parmar, Simrit, additional, Iyer, Swaminathan, additional, Westin, Jason, additional, Fayad, Luis, additional, Rodriguez, M. Alma, additional, Neelapu, Sattva, additional, Nastoupil, Loretta, additional, Flowers, Christopher R., additional, Dabaja, Bouthaina S., additional, and Pinnix, Chelsea C., additional

Published
2020
Full Text
View/download PDF

373. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities

Author

Gutierrez, Cristina, primary, Brown, Anne Rain T., additional, Herr, Megan M., additional, Kadri, Sameer S., additional, Hill, Brian, additional, Rajendram, Prabalini, additional, Duggal, Abhijit, additional, Turtle, Cameron J., additional, Patel, Kevin, additional, Lin, Yi, additional, May, Heather P., additional, Gallo de Moraes, Alice, additional, Maus, Marcela V., additional, Frigault, Mathew J., additional, Brudno, Jennifer N., additional, Athale, Janhavi, additional, Shah, Nirali N., additional, Kochenderfer, James N., additional, Dharshan, Ananda, additional, Beitinjaneh, Amer, additional, Arias, Alejandro S., additional, McEvoy, Colleen, additional, Mead, Elena, additional, Stephens, R. Scott, additional, Nates, Joseph L., additional, Neelapu, Sattva S., additional, and Pastores, Stephen M., additional

Published
2020
Full Text
View/download PDF

374. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Author

Chin, Collin K., primary, Rodriguez, Maria A., additional, Qing, Yun, additional, Feng, Lei, additional, Samaniego, Felipe, additional, Jain, Preetesh, additional, Noorani, Mansoor, additional, Fowler, Nathan H., additional, Fayad, Luis E., additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Hagemeister, Frederick B., additional, Flowers, Christopher R., additional, and Nastoupil, Loretta J., additional

Published
2020
Full Text
View/download PDF

375. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

Author

Pinnix, Chelsea C., primary, Gunther, Jillian R., primary, Dabaja, Bouthaina S., primary, Strati, Paolo, primary, Fang, Penny, primary, Hawkins, Misha C., primary, Adkins, Sherry, primary, Westin, Jason, primary, Ahmed, Sairah, primary, Fayad, Luis, primary, Lee, Hun Ju, primary, Nair, Ranjit, primary, Steiner, Raphael E., primary, Iyer, Swaminathan P., primary, Rodriguez, M. Alma, primary, Wang, Michael, primary, Flowers, Christopher, primary, Neelapu, Sattva S., primary, and Nastoupil, Loretta J., primary

Published
2020
Full Text
View/download PDF

376. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Author

Neelapu, Sattva S., primary, Jacobson, Caron A., primary, Oluwole, Olalekan O., primary, Munoz, Javier, primary, Deol, Abhinav, primary, Miklos, David B., primary, Bartlett, Nancy L., primary, Braunschweig, Ira, primary, Jiang, Yizhou, primary, Kim, Jenny J., primary, Zheng, Lianqing, primary, Rossi, John M., primary, and Locke, Frederick L., primary

Published
2020
Full Text
View/download PDF

378. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

Author

Strati, Paolo, primary, furqan, fateeha, additional, Westin, Jason, additional, Fayad, Luis, additional, Ahmed, Sairah, additional, Lee, Hun Ju, additional, Iyer, Swaminathan Padmanabhan, additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Wang, Michael, additional, Pinnix, Chelsea Camille, additional, Flowers, Christopher, additional, Horowitz, Sandra B., additional, Classen, Catherine, additional, Mistry, Haleigh, additional, and Neelapu, Sattva Swarup, additional

Published
2020
Full Text
View/download PDF

379. Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma.

Author

Galon, Jerome, primary, Scholler, Nathalie, additional, Perbost, Regis, additional, Turcan, Sarah, additional, Danan, Corinne, additional, Locke, Frederick Lundry, additional, Neelapu, Sattva Swarup, additional, Miklos, David Bernard, additional, Jacobson, Caron A., additional, Lekakis, Lazaros J., additional, Lin, Yi, additional, Ghobadi, Armin, additional, Chou, Justin, additional, Wang, Zixing, additional, Xue, Allen, additional, Rossi, John M., additional, and Bot, Adrian, additional

Published
2020
Full Text
View/download PDF

380. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).

Author

Ahmed, Sairah, primary, furqan, fateeha, additional, Strati, Paolo, additional, Westin, Jason, additional, Fayad, Luis, additional, Hagemeister, Frederick B., additional, Lee, Hun Ju, additional, Iyer, Swaminathan Padmanabhan, additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Wang, Michael, additional, Pinnix, Chelsea Camille, additional, Flowers, Christopher, additional, Horowitz, Sandra B., additional, Hawkins, Misha, additional, and Neelapu, Sattva Swarup, additional

Published
2020
Full Text
View/download PDF

381. Clinicopathologic features and outcomes of de novo transformed indolent lymphoma.

Author

Chin, Collin K, primary, Cheah, Chan, additional, Jain, Preetesh, additional, Fowler, Nathan Hale, additional, Fayad, Luis, additional, Westin, Jason, additional, Rodriguez, Maria Alma, additional, Noorani, Mansoor, additional, Neelapu, Sattva Swarup, additional, Hagemeister, Fredrick B., additional, Medeiros, L Jeffrey, additional, Vega, Francisco, additional, Samaniego, Felipe, additional, Flowers, Christopher, additional, and Nastoupil, Loretta J., additional

Published
2020
Full Text
View/download PDF

382. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study.

Author

Chin, Collin K, primary, Lim, Kenneth JC, additional, Lewis, Katharine L, additional, Jain, Preetesh, additional, Qing, Yun, additional, Feng, Lei, additional, Cheah, Chan, additional, Seymour, John Francis, additional, Ritchie, David, additional, Burbury, Kate, additional, Tam, Constantine Si Lun, additional, Fowler, Nathan Hale, additional, Fayad, Luis, additional, Westin, Jason, additional, Neelapu, Sattva Swarup, additional, Hagemeister, Fredrick B., additional, Samaniego, Felipe, additional, Flowers, Christopher, additional, Nastoupil, Loretta J., additional, and Dickinson, Michael, additional

Published
2020
Full Text
View/download PDF

383. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Author

Jacobson, Caron A., primary, Chavez, Julio C., additional, Sehgal, Alison R., additional, William, Basem M., additional, Munoz, Javier, additional, Salles, Gilles A., additional, Casulo, Carla, additional, Munshi, Pashna N., additional, Maloney, David G., additional, De Vos, Sven, additional, Reshef, Ran, additional, Leslie, Lori A., additional, Yakoub-Agha, Ibrahim, additional, Oluwole, Olalekan O., additional, Fung, Henry C., additional, Plaks, Vicki, additional, Yang, Yin, additional, Lee, Jennifer, additional, Avanzi, Mauro P., additional, and Neelapu, Sattva Swarup, additional

Published
2020
Full Text
View/download PDF

384. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

Author

Neelapu, Sattva Swarup, primary, Munoz, Javier, additional, Locke, Frederick Lundry, additional, Miklos, David Bernard, additional, Brown, Robert, additional, McDevitt, Jennifer T., additional, Mardiros, Armen, additional, Demirhan, Eren, additional, Konto, Cyril, additional, and Tees, Michael Timothy, additional

Published
2020
Full Text
View/download PDF

385. M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.

Author

Nair, Ranjit, primary, Pinnix, Chelsea Camille, additional, Gunther, Jillian Rebecca, additional, Strati, Paolo, additional, Westin, Jason, additional, Fayad, Luis, additional, Hagemeister, Fredrick B., additional, Iyer, Swaminathan Padmanabhan, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Dabaja, Bouthaina Shbib, additional, Fang, Penny, additional, Flowers, Christopher, additional, Noorani, Mansoor, additional, Feng, Lei, additional, Neelapu, Sattva Swarup, additional, Ahmed, Sairah, additional, and Lee, Hun Ju, additional

Published
2020
Full Text
View/download PDF

386. Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

Author

Locke, Frederick Lundry, primary, Bartlett, Nancy L., additional, Jacobson, Caron A., additional, Oluwole, Olalekan O., additional, Munoz, Javier, additional, Lekakis, Lazaros J., additional, Topp, Max S., additional, Avivi, Irit, additional, Kim, Jenny J., additional, Chu, Rong, additional, Zheng, Lianqing, additional, Rossi, John M., additional, Bot, Adrian, additional, and Neelapu, Sattva Swarup, additional

Published
2020
Full Text
View/download PDF

387. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Author

Zhao, Shuangtao, primary, Kanagal‐Shamanna, Rashmi, additional, Navsaria, Lucy, additional, Ok, Chi Young, additional, Zhang, Shaojun, additional, Nomie, Krystle, additional, Han, Guangchun, additional, Hao, Dapeng, additional, Hill, Holly A., additional, Jiang, Changying, additional, Yao, Yixin, additional, Nastoupil, Loretta, additional, Westin, Jason, additional, Fayad, Luis, additional, Nair, Ranjit, additional, Steiner, Raphel, additional, Ahmed, Sairah, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P., additional, Oriabure, Onyeka, additional, Chen, Wendy, additional, Song, Xingzhi, additional, Zhang, Jianhua, additional, Badillo, Maria, additional, Moghrabi, Omar, additional, Aranda, Jorge, additional, Tang, Guilin, additional, Yin, C. Cameron, additional, Patel, Keyur, additional, Medeiros, Leonard Jeffrey, additional, Li, Shaoying, additional, Vega, Francisco, additional, Thirumurthi, Selvi, additional, Xu, Guofan, additional, Neelapu, Sattva, additional, Flowers, Christopher R., additional, Romaguera, Jorge, additional, Fowler, Nathan, additional, Wang, Linghua, additional, Wang, Michael L., additional, and Jain, Preetesh, additional

Published
2020
Full Text
View/download PDF

389. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Author

Jain, Preetesh, primary, Zhang, Shaojun, primary, Kanagal-Shamanna, Rashmi, primary, Ok, Chi Young, primary, Nomie, Krystle, primary, Gonzalez, Graciela Nogueras, primary, Gonzalez-Pagan, Omarya, primary, Hill, Holly A., primary, Lee, Hun Ju, primary, Fayad, Luis, primary, Westin, Jason, primary, Nastoupil, Loretta, primary, Hagemeister, Frederick, primary, Chen, Wendy, primary, Oriabure, Onyeka, primary, Badillo, Maria, primary, Jiang, Changying, primary, Yixin, Yao, primary, Li, Shaoying, primary, Tang, Guilin, primary, Yin, C. Cameron, primary, Patel, Keyur P., primary, Medeiros, Leonard Jeffrey, primary, Nair, Ranjit, primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Thirumurthi, Selvi, primary, Champlin, Richard, primary, Xu, Guofan, primary, Tinsu, Pan, primary, Santos, David, primary, Wang, Ruiping, primary, Han, Guangchun, primary, Zhang, Jianhua, primary, Song, Xingzhi, primary, Neelapu, Sattva, primary, Romaguera, Jorge, primary, Futreal, Andy, primary, Flowers, Christopher, primary, Fowler, Nathan, primary, Wang, Linghua, primary, and Wang, Michael L., primary

Published
2020
Full Text
View/download PDF

390. The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

Author

Fowler, Nathan H., primary, Nastoupil, Loretta, additional, De Vos, Sven, additional, Knapp, Mark, additional, Flinn, Ian W., additional, Chen, Robert, additional, Advani, Ranjana H., additional, Bhatia, Sumeet, additional, Martin, Peter, additional, Mena, Raul, additional, Davis, Richard Eric, additional, Neelapu, Sattva S., additional, Eckert, Karl, additional, Ping, Jerry, additional, Co, Melannie, additional, Beaupre, Darrin M., additional, Neuenburg, Jutta K., additional, and Palomba, M. Lia, additional

Published
2020
Full Text
View/download PDF

392. A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)

Author

Neelapu, Sattva S., primary, Locke, Frederick L., additional, Bartlett, Nancy L., additional, Lekakis, Lazaros J., additional, Reagan, Patrick M., additional, Miklos, David B., additional, Jacobson, Caron A., additional, Braunschweig, Ira, additional, Oluwole, Olalekan O., additional, Siddiqi, Tanya, additional, Lin, Yi, additional, Crump, Michael, additional, Kuruvilla, John, additional, Neste, Eric Van Den, additional, Farooq, Umar, additional, Navale, Lynn, additional, DePuy, Venita, additional, Kim, Jenny J., additional, and Gisselbrecht, Christian, additional

Published
2020
Full Text
View/download PDF

393. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Author

Mondello, Patrizia, primary, Tadros, Saber, additional, Teater, Matt, additional, Fontan, Lorena, additional, Chang, Aaron Y., additional, Jain, Neeraj, additional, Yang, Haopeng, additional, Singh, Shailbala, additional, Ying, Hsia-Yuan, additional, Chu, Chi-Shuen, additional, Ma, Man Chun John, additional, Toska, Eneda, additional, Alig, Stefan, additional, Durant, Matthew, additional, de Stanchina, Elisa, additional, Ghosh, Sreejoyee, additional, Mottok, Anja, additional, Nastoupil, Loretta, additional, Neelapu, Sattva S., additional, Weigert, Oliver, additional, Inghirami, Giorgio, additional, Baselga, José, additional, Younes, Anas, additional, Yee, Cassian, additional, Dogan, Ahmet, additional, Scheinberg, David A., additional, Roeder, Robert G., additional, Melnick, Ari M., additional, and Green, Michael R., additional

Published
2020
Full Text
View/download PDF

394. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Author

Timmerman, John, primary, Herbaux, Charles, additional, Ribrag, Vincent, additional, Zelenetz, Andrew D., additional, Houot, Roch, additional, Neelapu, Sattva S., additional, Logan, Theodore, additional, Lossos, Izidore S., additional, Urba, Walter, additional, Salles, Gilles, additional, Ramchandren, Radhakrishnan, additional, Jacobson, Caron, additional, Godwin, John, additional, Carpio, Cecilia, additional, Lathers, Deanne, additional, Liu, Yali, additional, Neely, Jaclyn, additional, Suryawanshi, Satyendra, additional, Koguchi, Yoshinobu, additional, and Levy, Ronald, additional

Published
2020
Full Text
View/download PDF

396. Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Author

Gunther, Jillian R., primary, Pinnix, Chelsea C., additional, Glober, Gordon R., additional, Christopherson, Kaitlin M., additional, Fang, Penny, additional, Lee, Hun Ju, additional, Ahmed, Sairah, additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Strati, Paolo, additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, and Dabaja, Bouthaina S., additional

Published
2020
Full Text
View/download PDF

397. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Author

Liu, Enli, primary, Marin, David, additional, Banerjee, Pinaki, additional, Macapinlac, Homer A., additional, Thompson, Philip, additional, Basar, Rafet, additional, Nassif Kerbauy, Lucila, additional, Overman, Bethany, additional, Thall, Peter, additional, Kaplan, Mecit, additional, Nandivada, Vandana, additional, Kaur, Indresh, additional, Nunez Cortes, Ana, additional, Cao, Kai, additional, Daher, May, additional, Hosing, Chitra, additional, Cohen, Evan N., additional, Kebriaei, Partow, additional, Mehta, Rohtesh, additional, Neelapu, Sattva, additional, Nieto, Yago, additional, Wang, Michael, additional, Wierda, William, additional, Keating, Michael, additional, Champlin, Richard, additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2020
Full Text
View/download PDF

398. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Author

Overman, Michael, primary, Javle, Milind, additional, Davis, Richard E, additional, Vats, Pankaj, additional, Kumar-Sinha, Chandan, additional, Xiao, Lianchun, additional, Mettu, Niharika B, additional, Parra, Edwin R, additional, Benson, Al B, additional, Lopez, Charles D, additional, Munugalavadla, Veerendra, additional, Patel, Priti, additional, Tao, Lin, additional, Neelapu, Sattva, additional, and Maitra, Anirban, additional

Published
2020
Full Text
View/download PDF

400. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Author

Strati, Paolo, primary, Ahmed, Mohamed Amin, additional, Nastoupil, Loretta J., additional, Feng, Lei, additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Rodriguez, Maria A., additional, Samaniego, Felipe, additional, Wang, Michael, additional, Westin, Jason R., additional, Lee, Hun J., additional, Iyer, Swaminathan P., additional, Parmar, Simrit, additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Steiner, Raphael E., additional, Noorani, Mansoor, additional, Flowers, Christopher R., additional, Davis, R. Eric, additional, Fowler, Nathan H., additional, and Neelapu, Sattva S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results